Tvardi Therapeutics (TVRD) Other financing activities (2013 - 2025)

Tvardi Therapeutics (TVRD) posted Other financing activities of $1000.0 for Q4 2025, down 99.07% sequentially from $107000.0 in Q3 2025.

Tvardi Therapeutics (TVRD) Other financing activities (2013 - 2025) Analysis & Trends

Tvardi Therapeutics has reported Other financing activities for 12 years, with the latest figure at $1000.0 in Q4 2025.

Quarterly Other financing activities changed N/A year-over-year to $1000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $532000.0 (changed N/A YoY) and the FY2025 annual result came in at $532000.0, up 10540.0% from the prior year.
Other financing activities slipped to $1000.0 in Q4 2025 per TVRD's latest filing, from $107000.0 in the prior quarter.
Over five years, Other financing activities peaked at $560000.0 in Q1 2023 and troughed at -$1000.0 in Q3 2023.
A 4-year average of $143500.0 and a median of $63000.0 in 2022 frame the typical range for Other financing activities.
The widest YoY moves for Other financing activities: up 18566.67% in 2023, down 100.96% in 2023.
Over 4 years, Other financing activities stood at $319000.0 in 2021, then sank by 93.1% to $22000.0 in 2022, then plunged by 95.45% to $1000.0 in 2023, then changed by 0.0% to $1000.0 in 2025.
According to Business Quant data, Other financing activities over the past three periods registered $1000.0, $107000.0, and $421000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Tvardi Therapeutics	17.36 Mn	17.36 Mn	-

Download Data